The aim of the study was to investigate whether the antidepressant trazodone (TRZ), a serotonin-2 receptor antagonist/reuptake inhibitor, modifies g-amino-butyric acid (GABA) extracellular levels in the cerebral cortex, by acting on 5-HT 2A receptors, and through this mechanism increases 5-HT levels. For this purpose the effect of TRZ on the release of GABA was studied in adult male rats in synaptosomes, cortical slices, and bin vivoQ by microdialysis. In cortical slices, the release of both GABA and 5-HT was determined. GABA and 5-HT were identified and their levels quantified by HPLC. The inhibition of 5-HT uptake by TRZ was also measured. In synaptosomes, TRZ antagonized dose-dependently, at concentrations from 10 À10 to 10 À6 M, the increase in GABA release induced by (F)DOI, a 5-HT 2A/2C agonist, and the a receptor agonist phenylephrine, both 10 À6 M. The pIC 50 values were 8.31F0.24, and 5.99F0.52, respectively. In the same preparation, [ In cortical slices, TRZ exerted a biphasic effect on GABA release. At concentrations from 10 À10 to 10 À7 M it inhibited and from 10 À6 to 10 À4 M increased GABA release. 5-HT release was enhanced by TRZ throughout the entire range of concentrations tested. However, the increase was delayed after low and rapid after high concentrations. AMI-193, a 5-HT 2A antagonist (10 À10 to 10 À5 M), reduced GABA release in a dose-response manner, while it induced an increase of 5-HT outflow. On the contrary, (F)DOI (10 À10 to 10 À5 M) increased GABA release and inhibited 5-HT levels. Perfusion with the GABA A receptor antagonist bicuculline was also followed by an increase in 5-HT release.
H]5-HT accumulation was inhibited by citalopram and TRZ with pIC 50 of 7.8F0.44 and 5.9F0.09, respectively, a finding confirming the weak activity of TRZ in comparison with a SSRI.
In cortical slices, TRZ exerted a biphasic effect on GABA release. At concentrations from 10 À10 to 10 À7 M it inhibited and from 10 À6 to 10 À4 M increased GABA release. 5-HT release was enhanced by TRZ throughout the entire range of concentrations tested. However, the increase was delayed after low and rapid after high concentrations. AMI-193, a 5-HT 2A antagonist (10 À10 to 10 À5 M), reduced GABA release in a dose-response manner, while it induced an increase of 5-HT outflow. On the contrary, (F)DOI (10 À10 to 10 À5 M) increased GABA release and inhibited 5-HT levels. Perfusion with the GABA A receptor antagonist bicuculline was also followed by an increase in 5-HT release.
In microdialysis experiments, TRZ 1.25 mg kg À1 s.c. brought about a decrease in GABA extracellular levels, while an increase was found after the dose of 2.5 mg kg
À1 . These findings demonstrate that TRZ, at concentrations which do not inhibit 5-HT uptake, reduces the cortical GABAergic tone by decreasing GABA extracellular levels, through the blockade of 5-HT 2A receptors. The attenuation of GABAergic tone is responsible for an increase in 5-HT levels. A further increase also results from 5-HT uptake inhibition caused by higher doses of TRZ. The ensuing high 5-HT levels enhance GABA release, which in turn inhibits 5-HT release. D 2004 Elsevier Inc. All rights reserved.
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Introduction
Trazodone (TRZ) was introduced in the 1960s as an antidepressant drug and is still widely used (Baldessarini, 2001) . Since it is a weak inhibitor of serotonin (5-HT) reuptake (Owens et al., 1997) , it has been considered different from tricyclic antidepressant (TCAs) and selective serotonin reuptake inhibitors (SSRIs). Pazzagli et al. (1999) demonstrated that TRZ administration brings about a large increase in 5-HT extracellular level in rat's cerebral cortex. Abbreviations: propyl]-1-phenyl-1,3,8-triazaspiro[4.5]-decan-4-one; AUC, area under the curve; DOI, (F)-2,5-dimethoxy-4-iodophenyl-2-aminopropane; GABA, g-amino-butyric acid; 5-HT, serotonin; SARI, serotonin receptor antagonist/reuptake inhibitor; SSRI, selective 5-HT reuptake inhibitors; TCAs, tricyclic antidepressants; TRZ, trazodone.
